A Phase 2/3 interventional study of AZD3759 and Erlotinib in Non-small Cell Lung Cancer, EGFR Gene Mutation and Brain Metastases, sponsored by Alpha Biopharma (Jiangsu) Co., Ltd.. Completed at 58 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-10.
Sponsored by Alpha Biopharma (Jiangsu) Co., Ltd. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,881 studies in Carcinoma, Non-Small-Cell Lung with a site in China — 763 open to participants now, 987 under way, 203 of them phase 3. Carcinoma, Non-Small-Cell Lung · China.
Among the 1,881 studies in Carcinoma, Non-Small-Cell Lung with a site in China, this one is the 212th largest by enrollment of the 1,594 interventional ones that give a count, is one of 90 that started in 2018, is one of 38 in phase 2/3, and was the 495th registered.
7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →763 of the 1,881 studies in Carcinoma, Non-Small-Cell Lung with a site in China are open now. Recruiting first, the newest first:
Full-Life Technologies UK Limited · Sites in China, United States, Australia
Ages 18+
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Sichuan Baili Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Ruijin Hospital · Sites in China
Ages 18+
Daiichi Sankyo · Sites in China, United States, Argentina and 10 more countries
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,881 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 361 · Phase 2 849 · Phase 3 404 · Phase 4 40
First in 1996; this study’s year is marked. 90 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 492 is above the median of 62 across 6,028 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 100 across the 1,594 interventional studies, 200 across the 287 observational. Of the 454 that completed or were terminated, 130 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
805 of 1,881 have an industry lead sponsor. The 10 most frequent:
Alpha Biopharma (Jiangsu) Co., Ltd. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Alpha Biopharma (Jiangsu) Co., Ltd. has 1 study filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
224 of the studies in Carcinoma, Non-Small-Cell Lung with a site in China that are under way reach primary completion within a year, 33 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06448312Phase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2026-11 |
| NCT06704620Phase 3Tianjin Medical University Cancer Institute and HospitalStudy of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist(Diphenhydramine)in Advanced and Metastatic Non-Small Cell Lung Cancer | 2026-11 |
| NCT05429463Phase 3Second Affiliated Hospital, Zhejiang University, School of MedicineNeoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC(neoSCORE Ⅱ) | 2026-11-30 |
| NCT06711900Phase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | 2026-12 |
| NCT06382129Phase 3Sichuan Baili Pharmaceutical Co., Ltd.A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02) | 2026-12 |
Add all 224 to your calendar (.ics) → With an account.
Among the 1,881 studies in Carcinoma, Non-Small-Cell Lung with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The first-line treatment with single agent AZD3759 results in superior Progression Free Survival (PFS) compared to Standard of Care (SoC) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI), in patients with advanced EGFR mutation positive non-small cell lung cancer (NSCLC) with Central Nervous System (CNS) metastasis
This is a Phase II/III randomized, open-label, multicenter study to compare the efficacy and safety of first line single-agent AZD3759 vs. Erlotinib or Gefitinib treatment in patients with advanced EGFR mutation positive NSCLC with CNS metastases.
Eligible patients with documented EGFR mutation+ (L858R and/or Exon 19Del) TKI-naïve advanced NSCLC and documented intracranial disease will be enrolled.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AZD3759 group will receive a 200 mg twice daily dose of AZD3759
Drug: AZD3759
SoC EGFR-TKI Erlotinib or Gefitinib Group will get EGFRTKI Erlotinib 150 mg or Gefitinib 250 mg PO Q.D
Drug: Erlotinib · Drug: Gefitinib
PFS assessed by Blinded Independent Central Radiological
To assess if first line treatment with AZD3759 results in significant PFS efficacy compared to Gefitinib or Erlotinib as determined by Blinded Independent Central Radiological (BICR) review using RECIST 1.1.
Time frame: 48 months
PFS assess by investigator
Investigator assessment of PFS using RECIST 1.1
Time frame: 48 months
Intracranial PFS (iPFS) assessed by investigator
Intracranial PFS (iPFS) assessed by investigator using RECIST 1.1
Time frame: 48 months
Intracranial PFS (iPFS) assessed by BICR
Intracranial PFS (iPFS) assessed by Blinded Independent Central Radiological (BICR) using RECIST 1.1
Time frame: 48 months
Extracranial PFS (ePFS) assessed by investigator
Extracranial PFS (ePFS) assessed by investigator using RECIST 1.1
Time frame: 48 months
Extracranial PFS (ePFS) assessed by BICR
Extracranial PFS (ePFS) assessed by Blinded Independent Central Radiological (BICR) using RECIST 1.1
Time frame: 48 months
Objective Response Rate (ORR) assessed by investigator using RECIST 1.1
Objective Response Rate (ORR) for Intracranial lesions and Extracranial lesions assessed separately by investigator using RECIST 1.1
Time frame: 48 months
Disease Control Rate (DCR) assessed by investigator using RECIST 1.1
Disease Control Rate (DCR) for Intracranial lesions and Extracranial lesions assessed separately by investigator using RECIST 1.1
Time frame: 48 months
Duration of Response (DoR) assessed by investigator using RECIST 1.1
Duration of Response (DoR) for Intracranial lesions and Extracranial lesions assessed separately by investigator using RECIST 1.1
Time frame: 48 months
Overall ORR assessed by investigator using RECIST 1.1
Overall ORR assessed by investigator using RECIST 1.1
Time frame: 48 months
Overall DCR assessed by investigator using RECIST 1.1
Overall DCR assessed by investigator using RECIST 1.1
Time frame: 48 months
Overall DoR assessed by investigator using RECIST 1.1
Overall DoR assessed by investigator using RECIST 1.1
Time frame: 48 months
ORR for Intracranial lesions assessed by investigator using RANO-BM
ORR for Intracranial lesions assessed by investigator using RANO-BM
Time frame: 48 months
DCR for Intracranial lesions assessed by investigator using RANO-BM
DCR for Intracranial lesions assessed by investigator using RANO-BM
Time frame: 48 months
DoR for Intracranial lesions assessed by investigator using RANO-BM
DoR for Intracranial lesions assessed by investigator using RANO-BM
Time frame: 48 months
Overall Survival
Overall Survival
Time frame: 48 months
Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30).
The 30-items questionnaire measures cancer patients' functioning and symptoms. The scale range of EORTC QLQ-C30 is 30-126. Lower values represent a better outcome.
Time frame: 48 months
Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire BN20 (EORTC QLQ-BN20).
The 20-items questionnaire was used among brain cancer patients. The scale range of EORTC BN20 is 20-80. Lower values represent a better outcome.
Time frame: 48 months
Neurological function improvement rate assessed by Mini-Mental Status Examination (MMSE)
Neurological function improvement rate assessed by Mini-Mental Status Examination (MMSE)
Time frame: 48 months
Neurological function improvement rate assessed by RANO-BM criteria
Neurological function improvement rate assessed by RANO-BM criteria
Time frame: 48 months
Number of participants with treatment-related Adverse Events as assessed by CTCAE v5.0
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time frame: 48 months
Number of participants with treatment-related Serious Adverse Events as assessed by CTCAE v5.0
Number of participants with treatment-related Serious Adverse Events as assessed by CTCAE v5.0
Time frame: 48 months
Incidence of laboratory abnormalities collected by hematology tests during the study as assessed by CTCAE v5.0
Incidence of laboratory abnormalities collected by hematology tests during the study as assessed by CTCAE v5.0
Time frame: 48 months
Incidence of laboratory abnormalities collected by biochemistry tests during the study as assessed by CTCAE v5.0
Incidence of laboratory abnormalities collected by biochemistry tests during the study as assessed by CTCAE v5.0
Time frame: 48 months
Incidence of laboratory abnormalities collected byurinalysis tests during the study as assessed by CTCAE v5.0
Incidence of laboratory abnormalities collected byurinalysis tests during the study as assessed by CTCAE v5.0
Time frame: 48 months
Rhythm, PR, R-R, QRS and QT intervals and an overall evaluation of ECG assessed during the study period.
Rhythm, PR, R-R, QRS and QT intervals and an overall evaluation of ECG assessed during the study period.
Time frame: 48 months
Systolic and Diastolic Blood Pressure assessed during the study period.
Systolic and Diastolic Blood Pressure assessed during the study period.
Time frame: 48 months
Pulse rate assessed during the study period.
Pulse rate to assessed during the study period.
Time frame: 48 months
Body temperature assessed during the study period.
Body temperature assessed during the study period.
Time frame: 48 months
PFS assess by BICR
Blinded Independent Central Radiological (BICR) assessment of PFS using modified RECIST 1.1.
Time frame: 48 months
Pop-PK analysis
Population pharmacokinetic analysis
Time frame: 48 months
Exposure-Response analysis
explore the correlation in exposure and efficacy, exposure and safety in the Study
Time frame: 48 months
Plan to share: No
Ran from Oct 2018 to primary completion in Jul 2022, 44 months.
Of 56 phase 2/3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 40. This study's 44 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AZD3759
Carcinoma, Non-Small-Cell Lung →
Alpha Biopharma (Jiangsu) Co., Ltd.